Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 3/20 | 0.44 |
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.42 |
| ▸ | JAK2 | O60674 | 5/20 | 0.40 |
| ▸ | JAK3 | P52333 | 5/20 | 0.40 |
| ▸ | PTK2 | Q05397 | 5/20 | 0.40 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.39 |
| ▸ | JAK1 | P23458 | 2/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14219068 | 0.93 | JAK2 (0.43) | CHEK1GPR119JAK2JAK3PTK2 | |
| SCHEMBL14218632 | 0.91 | CHEK1 (0.45) | CHEK1GPR119ROCK2JAK1PIK3CA | |
| SCHEMBL11931561 | 0.90 | CHEK1 (0.54) | CHEK1GPR119 | |
| SCHEMBL14219070 | 0.87 | CHEK1 (0.40) | CHEK1GPR119JAK2JAK3PTK2 | |
| SCHEMBL14218631 | 0.87 | CHEK1 (0.43) | CHEK1GPR119ROCK2JAK1PIK3CA | |
| SCHEMBL14218799 | 0.86 | CHEK1 (0.43) | CHEK1GPR119JAK2JAK3PTK2 | |
| SCHEMBL14219071 | 0.86 | CHEK1 (0.41) | CHEK1GPR119ROCK2JAK1PIK3CA | |
| SCHEMBL14232557 | 0.85 | CHEK1 (0.49) | CHEK1GPR119ROCK2JAK1PIK3CA | |
| SCHEMBL14219067 | 0.85 | CHEK1 (0.55) | CHEK1GPR119ROCK2JAK1PIK3CA | |
| SCHEMBL14232556 | 0.85 | CHEK1 (0.47) | CHEK1GPR119ROCK2JAK1PIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008045268-A2 | PYRAZOLOPYRIMIDINES AS CYCLIN DEPENDENT KINASE INHIBITORS | SCHERING CORPORATION (US) | 2008-04-17 | — | — | WO | disclosed |